QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
Share
Why It Matters
A new fund called PEPT lets you own many peptide companies at once. This is worth watching because the peptide medicine market is growing very fast.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.